PD 140248 is a novel broad-spectrum 7-pyrrolidinyl fluoronaphthyridines with a cyclopropyl or a difluorophenyl substitution at the 1 positions, respectively. It has been demonstrated to have excellent in vitro activity against gram-positive organisms. This compound was evaluated for its in vivo potencies against acute systemic infections in mice and in a mouse pneumococcal pneumonia model. Most remarkable was its comparative median protective value against methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. PD 140248 has excellent therapeutic potential against clinically important gram-positive pathogens when the drugs are administered both orally and parenterally. References: Shapiro MA, Dever JA, Joannides ET, Sesnie JC, Vanderroest SR. In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother. 1995 Oct;39(10):2183-6. PubMed PMID: 8619563; PubMed Central PMCID: PMC162910. 2: Steiert M, Schmitz FJ. PD-140248 (Parke-Davis & Co). IDrugs. 2000 Feb;3(2):223-7. PubMed PMID: 16107942. 3: Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. PubMed PMID: 8192468; PubMed Central PMCID: PMC284459. 4: Huband MD, Cohen MA, Meservey MA, Roland GE, Yoder SL, Dazer ME, Domagala JM. In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother. 1993 Dec;37(12):2563-70. PubMed PMID: 8109918; PubMed Central PMCID: PMC192739. 5: Domagala JM, Hagen SE, Joannides T, Kiely JS, Laborde E, Schroeder MC, Sesnie JA, Shapiro MA, Suto MJ, Vanderroest S. Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1- pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy. J Med Chem. 1993 Apr 2;36(7):871-82. PubMed PMID: 8385225. 6: García-Rodríguez JA, García Sánchez JE, Trujillano I, García Sánchez E, García García MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother. 1995 May;39(5):1194-5. PubMed PMID: 7625815; PubMed Central PMCID: PMC162710.

纯度：≥98%

CAS：147208-55-7